Q32 Bio Inc (QTTB)

$3.60 0.00 (N/A)
Market Cap 44.29M
Revenue (ttm) 0.00
Net Income (ttm) -47.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.61
Volume 105,800
Avg Vol 3,706,348
Day's Range N/A - N/A
Shares Out 12.30M
Stochastic %K 69%
Beta 0.13
Analysts Sell
Price Target $15.00

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic derm...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 999 0232
Address:
830 Winter Street, Waltham, United States
DandyTrades
DandyTrades Jan. 15 at 6:30 PM
$QTTB Wont be long now.....
0 · Reply
DandyTrades
DandyTrades Jan. 14 at 4:05 PM
$QTTB The ole pipeline means just a matter of time before another strong run in my opinion..... Just need more frequent updates....
0 · Reply
DandyTrades
DandyTrades Jan. 12 at 8:29 PM
$QTTB About time for them to drop some more news before to long isnt it......
0 · Reply
amaaaa
amaaaa Jan. 12 at 8:25 PM
$QTTB 👀👀
0 · Reply
DandyTrades
DandyTrades Jan. 12 at 4:29 PM
$QTTB Lets get a new HOD.....
0 · Reply
DandyTrades
DandyTrades Jan. 9 at 1:05 PM
$QTTB Screw it, lets see a spike to $7 today.... 🚀🚀🚀
0 · Reply
MrEsKurr
MrEsKurr Jan. 9 at 6:53 AM
$QTTB have a good feeling about this one. Im in at 3.60
1 · Reply
DandyTrades
DandyTrades Jan. 8 at 7:47 PM
$QTTB Lets go get another new HOD before close......
0 · Reply
amaaaa
amaaaa Jan. 8 at 4:27 PM
$QTTB what’s the news ?
0 · Reply
Stackdoe1
Stackdoe1 Jan. 8 at 4:18 PM
$QTTB $20
0 · Reply
Latest News on QTTB
Dow Dips 200 Points; Q32 Bio Shares Jump

Dec 1, 2025, 9:58 AM EST - 6 weeks ago

Dow Dips 200 Points; Q32 Bio Shares Jump

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Dec 1, 2025, 9:43 AM EST - 6 weeks ago

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 6 weeks ago

Q32 Bio Sells Complement Inhibitor ADX-097

AKBA

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:59 AM EST - 2 months ago

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Oct 21, 2025, 6:59 AM EDT - 3 months ago

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 28, 2025, 6:59 AM EDT - 5 months ago

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 6:59 AM EDT - 5 months ago

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Jun 25, 2025, 6:59 AM EDT - 7 months ago

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:59 AM EDT - 9 months ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 30, 2025, 6:59 AM EDT - 9 months ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Apr 16, 2025, 6:59 AM EDT - 9 months ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 6:59 AM EDT - 11 months ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Mar 8, 2025, 11:00 AM EST - 11 months ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Feb 28, 2025, 9:00 AM EST - 11 months ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Feb 26, 2025, 6:59 AM EST - 11 months ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Feb 10, 2025, 4:05 PM EST - 1 year ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Dec 11, 2024, 11:32 AM EST - 1 year ago

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Dec 10, 2024, 4:05 PM EST - 1 year ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:59 AM EST - 1 year ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Oct 14, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Aug 29, 2024, 3:40 AM EDT - 1 year ago

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

Aug 1, 2024, 4:54 PM EDT - 1 year ago

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

EBS HE HUMA SAVA SERV

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

Jul 1, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Joins Russell 3000® Index

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Mar 25, 2024, 4:15 PM EDT - 1 year ago

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

DandyTrades
DandyTrades Jan. 15 at 6:30 PM
$QTTB Wont be long now.....
0 · Reply
DandyTrades
DandyTrades Jan. 14 at 4:05 PM
$QTTB The ole pipeline means just a matter of time before another strong run in my opinion..... Just need more frequent updates....
0 · Reply
DandyTrades
DandyTrades Jan. 12 at 8:29 PM
$QTTB About time for them to drop some more news before to long isnt it......
0 · Reply
amaaaa
amaaaa Jan. 12 at 8:25 PM
$QTTB 👀👀
0 · Reply
DandyTrades
DandyTrades Jan. 12 at 4:29 PM
$QTTB Lets get a new HOD.....
0 · Reply
DandyTrades
DandyTrades Jan. 9 at 1:05 PM
$QTTB Screw it, lets see a spike to $7 today.... 🚀🚀🚀
0 · Reply
MrEsKurr
MrEsKurr Jan. 9 at 6:53 AM
$QTTB have a good feeling about this one. Im in at 3.60
1 · Reply
DandyTrades
DandyTrades Jan. 8 at 7:47 PM
$QTTB Lets go get another new HOD before close......
0 · Reply
amaaaa
amaaaa Jan. 8 at 4:27 PM
$QTTB what’s the news ?
0 · Reply
Stackdoe1
Stackdoe1 Jan. 8 at 4:18 PM
$QTTB $20
0 · Reply
Zeeshan98
Zeeshan98 Jan. 8 at 4:03 PM
$QTTB
0 · Reply
DandyTrades
DandyTrades Jan. 8 at 3:55 PM
$QTTB On the road to $4 baby......
0 · Reply
Dipps
Dipps Jan. 8 at 3:31 PM
$QTTB
0 · Reply
hitmongreen
hitmongreen Jan. 8 at 3:18 PM
$QTTB 🤔
0 · Reply
DandyTrades
DandyTrades Jan. 8 at 3:11 PM
$QTTB Wont be long now..... 🚀🚀🚀
0 · Reply
DandyTrades
DandyTrades Jan. 7 at 3:28 PM
$QTTB Lets go!!!! 🔥🔥🔥🚀🚀🚀 Dont sleep on this one......
0 · Reply
DandyTrades
DandyTrades Jan. 6 at 8:32 PM
$QTTB Lets go on and get back over $4......
0 · Reply
anj_rew
anj_rew Jan. 6 at 1:56 PM
$QTTB steadily climbing RSI, great financial health, current SP above SMA 200 / 50 / 15 and EMA 15. At this price target of $5 the stock is still a great buy in my opinion. Not financial advice.
0 · Reply
DandyTrades
DandyTrades Jan. 2 at 7:26 PM
$QTTB Some news anyday now would be good.... Lets go!!!!
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 5:29 AM
$QTTB
1 · Reply
ReverbRanger
ReverbRanger Dec. 26 at 2:12 PM
$QTTB Market structure is quietly punishing unfocused strategies. Balance sheet resilience remains an underappreciated swing factor. Demonstrated durability would lengthen investor time horizons. Investors will likely reward proof above promises.
0 · Reply